Asymptomatic persons are also tested at community-based facilities to prevent catastrophic outbreaks.Regular testing for COVID-19, influenza, and RSV is required to ensure safety when anti-virus guidelines deteriorate.
Because of Seegene’s two decades of experience, PCR testing will be reasonably priced. “Unconditional assistance to nations that join Seegene’s campaign to ensure a safe return to normalcy.”
Seegene Inc. (KQ096530), South Korea’s top molecular diagnostics (MDx) company, has started a global campaign to promote preventive and routine PCR testing in order to keep people safe and healthy in the COVID-19 age. The program, according to Dr. Jong-Yoon Chun, CEO of Seegene, aims to allow people to resume their normal lives while simultaneously helping global efforts to eradicate COVID-19 and prevent future outbreaks.
As governments around the world relax social distance limitations and repeal mask regulations, there has been an increase in influenza and common colds, which were not prominent during the two-year outbreak. Experts have also warned that serious mutations may go undetected because governments no longer provide free PCR testing. Individuals must now monitor their own health at their own expense to ensure safety.
Seegene’s “In-life PCR” effort is divided into two parts: 1) Asymptomatic testing for early viral detection 2) syndromic respiratory testing due to the removal of anti-virus limitations, and 3) greater PCR test accessibility due to lower pricing.
PCR testing can detect infected people with minimal or no symptoms as an initial test for asymptomatic patients. A study carried out by the United States According to the CDC, asymptomatic or presymptomatic people account for more than 60% of all COVID-19 transmission. Regular asymptomatic testing, even without a doctor’s order, is meant to reduce the spread of infections in community facilities such as schools, churches, and nursing homes while also allowing for a safe return to normal life.
Diagnosis of respiratory syndromic disease Syndromic testing is required to determine which virus is causing a patient’s symptoms and to determine the appropriate treatment. Seegene will supply the AllplexTM SARS-CoV-2 FluA/FluB/RSV Assay, which can identify SARS-CoV-2 (through the N, RdRP, and S genes), influenza A and B, and RSV (A/B) all at the same time. The World Health Organization recommends analyzing at least two SARS-CoV-2 target genes. Seegene’s test detects three COVID-19 variations to ensure accurate detection if new variants develop. The six-target exam incorporates two internal controls for greater accuracy.
PCR testing is becoming more widely available and affordable. PCR testing is frequently thought to be unreasonably expensive. Seegene will collaborate with hospitals and labs to reduce the cost of a test to under $12 in order to increase accessibility and encourage routine testing. Based on the company’s more than two decades of experience in molecular diagnostics, Seegene has decreased the entrance barrier by deploying high multiplex technologies.
“The ‘$12 PCR testing’ campaign will most certainly help Seegene achieve its objective of making molecular diagnostics available to everyone,” Dr. Xu added. Chun expressed this. I am confident that broad PCR testing will be the most effective way to end the COVID-19 epidemic. “Seegene will help cities and countries who work with us to better track and regulate the spread.”